Home
/
Enveric Biosciences, Inc.
/
Financials
/
Quarterly
Enveric Biosciences, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Enveric Biosciences, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2020
Mar 31, 2020
$9.60M
May 15, 2020
Q3
2019
Sep 30, 2019
$9.15M
Nov 8, 2019
Q2
2019
Jun 30, 2019
$11.02M
Aug 14, 2019
Q1
2020
Mar 31, 2019
$10.69M
May 15, 2020
Q3
2019
Sep 30, 2018
$10.58M
Nov 8, 2019
Q2
2019
Jun 30, 2018
$11.08M
Aug 14, 2019
Q1
2019
Mar 31, 2018
$11.06M
May 14, 2019
Q3
2018
Sep 30, 2017
$12.53M
Nov 14, 2018
Q2
2018
Jun 30, 2017
$12.27M
Aug 14, 2018
Q1
2018
Mar 31, 2017
$12.34M
May 15, 2018
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2020
Sep 30, 2020
$8.48M
Nov 16, 2020
Q2
2020
Jun 30, 2020
$8.25M
Aug 14, 2020
Q3
2020
Sep 30, 2019
$9.15M
Nov 16, 2020
Q2
2020
Jun 30, 2019
$11.02M
Aug 14, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2016
Sep 30, 2016
$10.06M
Nov 14, 2016
Q2
2016
Jun 30, 2016
$6.69M
Aug 12, 2016
Q1
2016
Mar 31, 2016
$7.01M
May 16, 2016
Q3
2016
Sep 30, 2015
$4.46M
Nov 14, 2016
Q2
2016
Jun 30, 2015
$3.93M
Aug 12, 2016
Q1
2015
Jun 30, 2015
$3.93M
Aug 18, 2015
Q1
2016
Mar 31, 2015
$4.28M
May 16, 2016
Q1
2015
Jun 30, 2014
$3.99M
Aug 18, 2015
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.87M)
Nov 14, 2025
Q3
2025
Jun 30, 2025
($2.52M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($2.52M)
Aug 14, 2025
Q3
2025
Mar 31, 2025
($2.18M)
Nov 14, 2025
Q2
2025
Mar 31, 2025
($2.18M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($2.18M)
May 14, 2025
Q3
2025
Sep 30, 2024
($2.08M)
Nov 14, 2025
Q3
2025
Jun 30, 2024
($1.88M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($1.88M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.46M)
May 14, 2025
Q2
2025
Mar 31, 2024
($2.46M)
Aug 14, 2025
Q3
2025
Mar 31, 2024
($2.46M)
Nov 14, 2025
Q3
2024
Sep 30, 2023
($2.82M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($6.36M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($6.36M)
Aug 12, 2024
Q2
2024
Mar 31, 2023
($4.68M)
Aug 12, 2024
Q3
2024
Mar 31, 2023
($4.68M)
Nov 14, 2024
Q1
2024
Mar 31, 2023
($4.68M)
May 15, 2024
Q3
2023
Sep 30, 2022
($2.48M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($2.79M)
Aug 11, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.87M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($2.52M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($2.19M)
May 14, 2025
Q3
2025
Sep 30, 2024
($2.08M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($1.90M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($2.48M)
May 14, 2025
Q3
2024
Sep 30, 2023
($3.45M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($5.76M)
Aug 12, 2024
Q1
2024
Mar 31, 2023
($4.86M)
May 15, 2024
Q3
2023
Sep 30, 2022
($5.66M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($4.71M)
Aug 11, 2023
Q1
2023
Mar 31, 2022
($4.80M)
May 15, 2023
Q3
2022
Sep 30, 2021
($3.52M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($3.36M)
Aug 12, 2022
Q1
2022
Mar 31, 2021
($6.76M)
May 13, 2022
Q3
2021
Sep 30, 2020
($489.8K)
Nov 15, 2021
Q2
2021
Jun 30, 2020
($767.5K)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($836.7K)
May 17, 2021
Q3
2020
Sep 30, 2019
($1.57M)
Nov 16, 2020
Q2
2020
Jun 30, 2019
($1.48M)
Aug 14, 2020